{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "22860709",
  "DateCompleted": {
    "Year": "2013",
    "Month": "01",
    "Day": "07"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "04",
    "Day": "16"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2012",
        "Month": "08",
        "Day": "04"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "10.1517/14656566.2012.709234"
    ],
    "Journal": {
      "ISSN": "1744-7666",
      "JournalIssue": {
        "Volume": "13",
        "Issue": "13",
        "PubDate": {
          "Year": "2012",
          "Month": "Sep"
        }
      },
      "Title": "Expert opinion on pharmacotherapy",
      "ISOAbbreviation": "Expert Opin Pharmacother"
    },
    "ArticleTitle": "S-1 for the treatment of gastrointestinal cancer.",
    "Pagination": {
      "StartPage": "1943",
      "EndPage": "1959",
      "MedlinePgn": "1943-59"
    },
    "Abstract": {
      "AbstractText": [
        "5-Fluorouracil (5-FU)-based regimens are used worldwide as the standard treatment in chemotherapy for gastric cancer. S-1 , a fourth-generation oral fluoropyrimidine that combines tegafur and two biochemical modulators: gimeracil and oteracil potassium, is now attracting considerable interest.",
        "This review addresses the clinical evidence of S-1 in gastrointestinal malignancies, such as gastric, colorectal, pancreatic and biliary tract cancers. S-1 has demonstrated advantages over standard therapies, in both advanced and postoperative settings, in large Phase III studies. S-1 alone or S-1 plus cisplatin is recommended in the 2010 Gastric Cancer Treatment Guidelines, by the Japanese Gastric Cancer Association. Results from Phase III studies have demonstrated that S-1 in combination with chemotherapies, such as cisplatin in gastric cancer, and irinotecan and oxaliplatin in colorectal cancers, is non-inferior to conventional 5-FU-based standard regimens, with the benefit of convenience and reduced toxicity.",
        "The excellent design of S-1 aimed to reduce toxicity by avoiding certain routes of degradation, and to enhance activity by reducing catabolism. This has provided not only a suitable alternative to 5-FU, but also higher efficacy."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Osaka University Graduate School of Medicine, Department of Frontier Science for Cancer and Chemotherapy, 2-2 Yamadaoka, Suita City, Osaka, 565-0871, Japan. taroh@cfs.med.osaka-u.ac.jp"
          }
        ],
        "LastName": "Satoh",
        "ForeName": "Taroh",
        "Initials": "T"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Sakata",
        "ForeName": "Yuh",
        "Initials": "Y"
      }
    ],
    "PublicationTypeList": [
      "Comparative Study",
      "Journal Article",
      "Review"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "England",
    "MedlineTA": "Expert Opin Pharmacother",
    "NlmUniqueID": "100897346",
    "ISSNLinking": "1465-6566"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antimetabolites, Antineoplastic"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Drug Combinations"
    },
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Organoplatinum Compounds"
    },
    {
      "RegistryNumber": "04ZR38536J",
      "NameOfSubstance": "Oxaliplatin"
    },
    {
      "RegistryNumber": "150863-82-4",
      "NameOfSubstance": "S 1 (combination)"
    },
    {
      "RegistryNumber": "1548R74NSZ",
      "NameOfSubstance": "Tegafur"
    },
    {
      "RegistryNumber": "5VT6420TIG",
      "NameOfSubstance": "Oxonic Acid"
    },
    {
      "RegistryNumber": "7673326042",
      "NameOfSubstance": "Irinotecan"
    },
    {
      "RegistryNumber": "Q20Q21Q62J",
      "NameOfSubstance": "Cisplatin"
    },
    {
      "RegistryNumber": "U3P01618RT",
      "NameOfSubstance": "Fluorouracil"
    },
    {
      "RegistryNumber": "XT3Z54Z28A",
      "NameOfSubstance": "Camptothecin"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Animals"
    },
    {
      "QualifierName": [
        "adverse effects",
        "therapeutic use"
      ],
      "DescriptorName": "Antimetabolites, Antineoplastic"
    },
    {
      "QualifierName": [
        "adverse effects",
        "therapeutic use"
      ],
      "DescriptorName": "Antineoplastic Combined Chemotherapy Protocols"
    },
    {
      "QualifierName": [
        "administration & dosage",
        "analogs & derivatives"
      ],
      "DescriptorName": "Camptothecin"
    },
    {
      "QualifierName": [
        "administration & dosage"
      ],
      "DescriptorName": "Cisplatin"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Drug Combinations"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Fluorouracil"
    },
    {
      "QualifierName": [
        "drug therapy",
        "pathology"
      ],
      "DescriptorName": "Gastrointestinal Neoplasms"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Irinotecan"
    },
    {
      "QualifierName": [
        "administration & dosage"
      ],
      "DescriptorName": "Organoplatinum Compounds"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Oxaliplatin"
    },
    {
      "QualifierName": [
        "adverse effects",
        "therapeutic use"
      ],
      "DescriptorName": "Oxonic Acid"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Practice Guidelines as Topic"
    },
    {
      "QualifierName": [
        "adverse effects",
        "therapeutic use"
      ],
      "DescriptorName": "Tegafur"
    }
  ]
}